Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer

被引:0
|
作者
Capuozzo, Maurizio [1 ]
Santorsola, Mariachiara [2 ]
Ianniello, Monica [3 ]
Ferrara, Francesco [1 ]
Zovi, Andrea [4 ]
Petrillo, Nadia [3 ]
Castiello, Rosa [3 ]
Fantuz, Maria Rosaria [3 ]
Ottaiano, Alessandro [2 ]
Savarese, Giovanni [3 ]
机构
[1] ASL Naples 3, Coordinamento Farmaceut, I-80056 Ercolano, Italy
[2] IRCCS G Pascale, Ist Nazl Tumori Napoli, Via M Semmola, I-80131 Naples, Italy
[3] Ctr Polidiagnost Strumentale Srl, AMES, Via Padre Carmine Fico 24, I-80013 Casalnuovo Di Napoli, Italy
[4] Minist Hlth, Viale Giorgio Ribotta 5, I-00144 Rome, Italy
关键词
prostate cancer; androgen-deprivation therapy; immunotherapy; PARP inhibitors; precision medicine; PHASE-III TRIAL; SIPULEUCEL-T; DOUBLE-BLIND; PLUS STANDARD; OPEN-LABEL; CASTRATION; IPILIMUMAB; IMMUNOTHERAPY; ENZALUTAMIDE; MULTICENTER;
D O I
10.3390/diseases12050087
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate cancer, a prevalent malignancy affecting the prostate gland, is a significant global health concern. Androgen-deprivation therapy (ADT) has proven effective in controlling advanced disease, with over 50% of patients surviving at the 10-year mark. However, a diverse spectrum of responses exists, and resistance to ADT may emerge over time. This underscores the need to explore innovative treatment strategies for effectively managing prostate cancer progression. Ongoing research endeavors persist in unraveling the complexity of prostate cancer and fostering the development of biologic and innovative approaches, including immunotherapies and targeted therapies. This review aims to provide a valuable synthesis of the dynamic landscape of emerging drug modalities in this context. Interestingly, the complexities posed by prostate cancer not only present a formidable challenge but also serve as a model and an opportunity for translational research and innovative therapies in the field of oncology.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Innovative approaches to the hormonal treatment of advanced prostate cancer
    Trachtenberg, J
    EUROPEAN UROLOGY, 1997, 32 : 78 - 80
  • [22] PARP inhibitors in advanced prostate cancer: when to use them?
    Diaz-Mejia, Nely
    Garcia-Illescas, David
    Morales-Barrera, Rafael
    Suarez, Cristina
    Planas, Jacques
    Maldonado, Xavier
    Carles, Joan
    Mateo, Joaquin
    ENDOCRINE-RELATED CANCER, 2021, 28 (08) : T79 - T93
  • [23] Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
    Lopez-Campos, Fernando
    Gajate, Pablo
    Romero-Laorden, Nuria
    Zafra-Martin, Juan
    Juan, Manel
    Hernando Polo, Susana
    Conde Moreno, Antonio
    Counago, Felipe
    BIOMEDICINES, 2022, 10 (03)
  • [24] Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer
    Higa, Julianna
    Wilenius, Kirk
    Savino, Shannon
    Larsen, Claire
    Scholz, Mark
    Vogelzang, Nicholas
    CLINICAL GENITOURINARY CANCER, 2020, 18 (04) : E397 - E401
  • [25] New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
    van Dodewaard-de Jong, Joyce M.
    Verheul, Henk M. W.
    Bloemendal, Haiko J.
    de Klerk, John M. H.
    Carducci, Michael A.
    van den Eertwegh, Alfons J. M.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 271 - 279
  • [26] Androgen deprivation and immunotherapy for the treatment of prostate cancer
    Gamat, Melissa
    McNeel, Douglas G.
    ENDOCRINE-RELATED CANCER, 2017, 24 (12) : T297 - T310
  • [27] Castration modalities in prostate cancer: Are they all equal?
    Ploussard, G.
    Bruyere, F.
    Culine, S.
    de La Taille, A.
    Hennequin, C.
    Oudard, S.
    Pfister, C.
    Ravery, V.
    Salomon, L.
    PROGRES EN UROLOGIE, 2016, 26 (05): : 319 - 328
  • [28] A NEW PARADIGM IN THE SYSTEMIC TREATMENT OF ADVANCED PROSTATE CANCER: THE EARLIER THE BETTER OR THE MORE THE BETTER
    Omrcen, Tomislav
    Murgic, Jure
    ACTA CLINICA CROATICA, 2024, 63 : 88 - 99
  • [29] Prostate cancer immunotherapy
    Mitsogiannis, Iraklis
    Tzelves, Lazaros
    Dellis, Athanasios
    Issa, Hussein
    Papatsoris, Athanasios
    Moussa, Mohammad
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (05) : 577 - 590
  • [30] Metastatic Prostate Cancer-A Review of Current Treatment Options and Promising New Approaches
    Posdzich, Philip
    Darr, Christopher
    Hilser, Thomas
    Wahl, Milan
    Herrmann, Ken
    Hadaschik, Boris
    Gruenwald, Viktor
    CANCERS, 2023, 15 (02)